BREAST LOBULAR CARCINOMA IN SITU
Clinical trials for BREAST LOBULAR CARCINOMA IN SITU explained in plain language.
Never miss a new study
Get alerted when new BREAST LOBULAR CARCINOMA IN SITU trials appear
Sign up with your email to follow new studies for BREAST LOBULAR CARCINOMA IN SITU, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Tamoxifen gel vs. pill: can a cream lower breast cancer risk?
Disease control TerminatedThis study tested whether a tamoxifen skin gel works as well as the standard tamoxifen pill to lower breast cancer risk in women with atypical hyperplasia or lobular carcinoma in situ (LCIS). About 65 women were enrolled, but the study was stopped early. The goal was to see short…
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for chemo-resistant breast cancer? trial tests targeted pill
Disease control TerminatedThis study tested a drug called abemaciclib in people with triple negative breast cancer that did not shrink with standard chemotherapy. The goal was to see if the drug could change the immune environment inside the tumor, making it more responsive. The trial was stopped early, b…
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:41 UTC
-
Genetic risk tool tested for breast cancer in minority women
Knowledge-focused TerminatedThis study looked at whether adding a genetic risk score to standard breast cancer risk assessments helps African American and Hispanic women decide about extra screening or prevention. The study enrolled 19 women at higher risk for breast cancer. The goal was to see if personali…
Matched conditions: BREAST LOBULAR CARCINOMA IN SITU
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC